

Eugenio Gaudio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2741565/publications.pdf>

Version: 2024-02-01

33
papers

954
citations

516710

16
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

1829
citing authors

#	ARTICLE	IF	CITATIONS
1	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.	7.0	237
2	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	7.0	92
3	Tcl1 interacts with Atm and enhances NF- κ B activation in hematologic malignancies. <i>Blood</i> , 2012, 119, 180-187.	1.4	48
4	The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. <i>Clinical Cancer Research</i> , 2019, 25, 5167-5176.	7.0	43
5	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , 2019, 104, e256-e259.	3.5	43
6	Pyrrolo[2,3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12023-12042.	6.4	43
7	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 936-948.	2.5	42
8	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , 2020, 4, 4124-4135.	5.2	37
9	Fhit ^Δ Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 147.	6.3	35
10	Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. <i>Oncotarget</i> , 2015, 6, 5059-5071.	1.8	29
11	The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , 2019, 104, 1633-1639.	3.5	28
12	Coplanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , 2020, 4, 819-829.	5.2	28
13	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1255-1264.	4.1	27
14	Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong <i>in vivo</i> antitumor activity in lymphoma. <i>Oncotarget</i> , 2016, 7, 58142-58147.	1.8	25
15	T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. <i>Frontiers in Oncology</i> , 2018, 8, 317.	2.8	23
16	BET bromodomain inhibitor birabresib in mantle cell lymphoma: <i>in vivo</i> activity and identification of novel combinations to overcome adaptive resistance. <i>ESMO Open</i> , 2018, 3, e000387.	4.5	21
17	Fhit Delocalizes Annexin A4 from Plasma Membrane to Cytosol and Sensitizes Lung Cancer Cells to Paclitaxel. <i>PLoS ONE</i> , 2013, 8, e78610.	2.5	18
18	A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells. <i>Oncotarget</i> , 2016, 7, 29927-29936.	1.8	16

#	ARTICLE	IF	CITATIONS
19	Heat shock protein 70 regulates Tc1 expression in leukemia and lymphomas. <i>Blood</i> , 2013, 121, 351-359.	1.4	15
20	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. <i>Haematologica</i> , 2019, 104, e307-e309.	3.5	14
21	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , 2019, 11, 775.	3.7	14
22	Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2018, 103, 2049-2058.	3.5	13
23	Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111545.	5.5	13
24	Single and combined BTK and PI3K γ inhibition with acalabrutinib and ACP α 319 in preclinical models of aggressive lymphomas. <i>British Journal of Haematology</i> , 2019, 187, 595-601.	2.5	12
25	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. <i>Blood Advances</i> , 2021, 5, 2467-2480.	5.2	10
26	TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. <i>British Journal of Haematology</i> , 2018, 183, 509-512.	2.5	6
27	Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. <i>PLoS ONE</i> , 2018, 13, e0208709.	2.5	6
28	The Fhit protein: an opportunity to overcome chemoresistance. <i>Aging</i> , 2016, 8, 3147-3150.	3.1	4
29	In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. <i>British Journal of Haematology</i> , 2019, 186, 149-152.	2.5	3
30	Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphoma than with Single BET or Crebbp/EP300 Inhibitors. <i>Blood</i> , 2018, 132, 4174-4174.	1.4	3
31	Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , 2019, 134, 2569-2569.	1.4	3
32	The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2021, 2, 586-601.	0.8	3
33	New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease. <i>Blood</i> , 2018, 132, 4173-4173.	1.4	0